source
- Biogen reports mixed results in mid‑stage trial of tau‑targeting Alzheimer’s therapyBiogen disclosed data from a Phase 2 study of its experimental Alzheimer’s drug that targets the tau protein. The trial showed a combination of positive and negative signals, with some measures ind…
- Biogen's anti-tau Alzheimer drug BIIB080 fails primary endpoint in Phase 2, but shows slower declineBiogen reported results of its Phase 2 trial of BIIB080, a tau-targeting therapy for Alzheimer’s disease. The study’s primary endpoint was not met, meaning the drug did not achieve the pre-specifi…